Radiopharm Theranostics Limited - Sponsored ADR
RADXRadiopharm Theranostics Limited - Sponsored ADR’s revenue for fiscal 2026 (year ended June 2026) was $1.9 million, down 20.2% from fiscal 2025.
After hours trading: 0.60, down 4.76%, last trade Fri 4:27pm Eastern.
Follow RADX
Alert me
Radiopharm Theranostics Limited - Sponsored ADR (RADX) Return on invested capital
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2026 | −195.2% | (21.70) |
| FY2025 | −173.5% | 162.68 |
| FY2024 | −336.1% | — |
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| BIVI BioVie Inc. compare | 0.00% |
| HIND Vyome Holdings, Inc. compare | 0.00% |
| AEON AEON Biopharma, Inc. compare | 0.00% |
| LSTA Lisata Therapeutics, Inc. compare | 0.00% |
| BCDA BioCardia, Inc. compare | 0.00% |
| PASG Passage Bio, Inc. compare | 0.00% |
| LEXX Lexaria Bioscience Corp. compare | −662.6% |
| RADX Radiopharm Theranostics Limited - Sponsored ADR | — |
| PBM Psyence Biomedical Ltd. compare | — |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.06% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)